Review uncovers how mesenchymal stem cells may improve outcomes in sepsis by targeting pyroptosis mechanisms.
Sepsis remains a highly critical and frequent condition in intensive care units, often leading to systemic inflammatory responses, immune suppression, and multiple organ dysfunction. Recent evidence has established pyroptosis, a type of pro-inflammatory programmed cell death, as a key mechanism in the development and progression of sepsis. This process is mediated by inflammasome activation, resulting in cell swelling, membrane rupture, and the release of pro-inflammatory cellular contents that amplify inflammatory cascades. Mesenchymal stem cells (MSCs), known for their anti-inflammatory, immunomodulatory, and tissue-regenerative capacities, have attracted attention as a promising therapeutic approach for sepsis. This review summarizes the mechanistic involvement of pyroptosis in septic pathogenesis and highlights recent advances in MSC-based therapies that target pyroptotic pathways, with the goal of elucidating the potential role of MSCs in the management of sepsis.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: